NW CORPORATE RESULTS | Dollar figures in thousands, except per share; parentheses denote losses. BsquareSoftware development March 31%1st...

Share story

Dollar figures in thousands, except per share; parentheses denote losses.

BsquareSoftware development March 31%1st QTR20082007CHGProfit$1,040$638+63.0Per share0.100.06+66.7Sales17,05815,096+13.0COMMENT: The Bellevue company, which specializes in software development for devices, saw an increase in the number of projects it worked on, but less revenue on average from each. Much of that resulted from its getting into Flash Lite service projects, which tend to be smaller. CEO Brian Crowley also said the company is encouraged by how it is building momentum in Japan.

Cell Therapeutics
Developer of cancer drugs
March 31 %
1st QTR 2008 2007 CHG
Profit ($54,604) ($28,739) -90.0
Per share (0.77) (0.76) -1.3
Revenue 3,394 20 +16,870
COMMENT: The loss per share remained almost unchanged because the number of shares nearly doubled along with the net loss. The company had gross sales of Zevalin totaling $3.8 million for the quarter.
Dendreon
Develops drugs targeting cancer
March 31 %
1st QTR 2008 2007 CHG
Profit ($19,516) ($30,858) +36.8
Per share (0.23) (0.38) +39.5
Revenue 31 80 -61.3
COMMENT: The Seattle company cut its operating expenses to $19.2 million from $32 million in the same quarter last year, partly because a clinical trial completed enrollment. After the quarter’s end, the company received $46 million in net proceeds from a stock placement.
Eddie Bauer
Retail sales
March 31 %
1st QTR 2008 2007 CHG
Profit ($19,299) ($44,781) +56.9
Per share (0.63) (1.47) +57.1
Sales 213,244 213,985 -0.3
COMMENT: Bellevue-based Eddie Bauer attributed a narrower first-quarter loss to a decline in its selling, general and administrative (SGA) expenses and a higher tax benefit. Its SGA expenses decreased from $111.8 million a year ago to $95.1 million. The company also said total comparable-store sales rose 0.5 percent during the quarter.
Emeritus
Assisted living
March 31 %
1st QTR 2008 2007 CHG
Profit ($25,968) ($9,735) -167
Per share (0.67) (0.53) -26.4
Sales 186,489 108,248 +72.3
COMMENT: Community operating expenses at the Seattle company rose to $121.6 million from $68.4 million a year earlier. About $49.1 million of the increase was due to the acquisition of 85 new communities, and $3.5 million was related to labor and related expenses. About $600,000 came from other operating expenses, particularly contracted services, food costs, utilities, supplies and marketing costs. General and administrative expenses rose to $14.6 million from $10.1 million a year earlier and included a $3.3 million increase in salary and benefit costs.
Nastech Pharmaceutical
Biotechnology
March 31 %
1st QTR 2008 2007 CHG
Profit ($16,518) ($11,540) -43.1
Per share (0.63) (0.47) -34.0
Revenue 1,263 4,992 -74.7
COMMENT: The Bothell company attributed its wider loss to lower revenue and $1.9 million in restructuring charges, primarily employee severance, stemming from the discontinuation of a clinical trial for its nasal osteoporosis treatment. It ended the quarter with about $24.1 million in cash and cash equivalents, compared with $41.6 million in the year-earlier period. In April, however, Nastech raised net proceeds of about $7.2 million in a registered direct offering.
Trubion
Develops biopharmaceuticals
March 31 %
1st QTR 2008 2007 CHG
Profit ($5,968) ($5,019) -18.9
Per share (0.33) (0.29) -13.8
Revenue 3,963 4,835 -18.0
COMMENT: Revenue included $1.5 million for the quarter, compared with $2 million in the same period last year, attributed to the $40 million upfront paid by Wyeth for an R&D agreement expected to run more than six years. The company ended the quarter with $72.1 million in cash and investments.